Skip to Main Content

Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer — avoiding the serious liver side effects and treatment discontinuations that have stalled similar efforts by Amgen.

The new safety data are a boost to Mirati’s efforts to expand the number of patients with KRAS-mutated lung cancer who might benefit from adagrasib — and help the drug grow into a commercial blockbuster.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment